UPCOMING SESSIONS in ET
Wed, Apr 29, 2026
10:00 – 11:00 PM UTC
ATTR-CM how do I know my treatment is working? Rebecca Hung MD Click To Register
UPCOMING SESSIONS in ET
Wed, Apr 29, 2026 · 10:00 – 11:00 PM UTC
ATTR-CM how do I know my treatment is working?
Rebecca Hung MD
Click To Register
View all sessions

Alnylam® Pharmaceuticals

Alnylam Rare Disease
alnylam_logo.png
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: Oct 09, 2023 - FDA Cites Insufficient Evidence of Clinical Meaningfulness - - No Clinical Safety, Study Conduct, Drug Quality or Manufacturing…
Read more
AMVUTTRA_logo.jpg
Alnylam Announces FDA Approval of AMVUTTRA™ (Vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration (FDA) approved AMVUTTRA(tm) (vutrisiran…
Read more
Logo_Alnylam_460-1.png
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration (FDA) has extended the review timeline of…
Read more
Logo_Alnylam_460-1.png
Alnylam Reports Positive Topline 18-Month Results From HELIOS-A Phase 3 Study of Vutrisiran in Patients With hATTR Amyloidosis With Polyneuropathy
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi…
Read more
Logo_Alnylam_460-1.png
Alnylam Reports Positive Topline Results From HELIOS-A Phase 3 Study of Vutrisiran in Patients With hATTR Amyloidosis With Polyneuropathy
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi…
Read more
Alnylam Rare Disease
Alnylam Pharmaceuticals - Linkedin
Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA…
Read more
alnylam_logo.png
FDA Approves Alnylam’s Onpattro for Polyneuropathy of hATTR Amyloidosis
The FDA today granted Alnylam Pharmaceuticals approval for a first-in-class small interfering ribonucleic acid (siRNA) treatment-the first therapy indicated for…
Read more
FDA_Logo.jpg
FDA Approves Patisiran Infusion for Hereditary Transthyretin-Mediated Amyloidosis
The FDA announced that it has approved patisiran infusion for the treatment of patients with peripheral nerve disease caused by hereditary transthyretin-mediated…
Read more